What is DotBio?
DotBio operates at the intersection of biotechnology and advanced pharmacology, specializing in the development of next-generation domain antibody therapies. At the core of its operations is the proprietary DotBody technology platform, which enables the creation of multi-functional and intracellular antibody therapies derived from stabilized human VH domains. This innovative approach facilitates the rapid generation of bi- and tri-specific antibodies, as well as sophisticated antibody-drug conjugates. By addressing the limitations of traditional therapeutic frameworks, DotBio provides the biopharmaceutical sector with high-precision tools designed to tackle complex disease targets that were previously considered undruggable.
How much funding has DotBio raised?
DotBio has raised a total of $5.6M across 1 funding round:
Other Financing Round
$5.6M
Other Financing Round (2023): $5.6M with participation from Proxima Ventures, Gaorong Capital, and AIM-HI Accelerator Fund
Key Investors in DotBio
Proxima Ventures
Proxima Ventures Ltd is a company that operates in the Investment Banking industry, providing strategic financial advisory and capital support to emerging enterprises.
Gaorong Capital
Gaorong Capital is an emerging venture capital firm focusing on seed and growth-stage investments, backed by a network of world-class entrepreneurs and industry leaders.
AIM-HI Accelerator Fund
AIM-HI Accelerator Fund is a non-profit organization dedicated to advancing breakthrough cancer research by providing essential seed funding to early-stage oncology startups.
What's next for DotBio?
Looking ahead, the strategic deployment of the $5.6M capital will be critical for DotBio as it scales its operations. The company is expected to prioritize the expansion of its DotBody platform, focusing on enhancing the efficacy and safety profiles of its intracellular antibody candidates. Furthermore, the firm will likely seek to deepen its collaborative efforts with global biopharmaceutical partners to validate its therapeutic solutions in clinical settings. As the company transitions into a more mature lifecycle stage, the focus will shift toward regulatory milestones and the commercialization of its lead assets, ensuring that its technological advancements translate into tangible patient outcomes and long-term shareholder value.
See full DotBio company page
